Michael Zinda

Company: Repare Therapeutics

Job title: Chief Scientific Officer, Executive Vice President, Head of Research & Development

Seminars:

Progress in PKMYT1 Inhibition: RP-6306 1:30 pm

Exploring the drug discovery process: target identification and validation, antitumor effect, pathway understanding, biomarkers Discussing potential indications? Forecasting the future of PKMYT1 to be monotherapy and/or combination dominated Sequencing dose schedule hypothesis? Latest data and future directionsRead more

day: Day Two